Cancer risks among the users of ergot-derived dopamine agonists for Parkinson's disease, a nationwide population-based survey

Parkinsonism and Related Disorders

Volumn 21, Issue 1, 2015, Pages 18-22

  Wang, Vinchi ^a,b   Chao, Tzu Hao ^a,b   Hsieh, Chung Chih ^a   Lin, Che Chen ^c   Kao, Chia Hung ^c,d  

^a CARDINAL TIEN HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cancer risks; Dopamine agonists; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; MONOAMINE OXIDASE B INHIBITOR; ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DRUG INDUCED CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PARKINSON DISEASE; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PROSTATE CANCER; SKIN CANCER; STOMACH CANCER; TAIWAN; URBANIZATION; URINARY TRACT CANCER; AGE; CASE CONTROL STUDY; CHEMICALLY INDUCED; HEALTH CARE PLANNING; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PUBLIC HEALTH; RISK; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; COMMUNITY HEALTH PLANNING; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NEOPLASMS; ODDS RATIO; PARKINSON DISEASE; RISK FACTORS; TAIWAN;

EID: 84918811078     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.10.015     Document Type: Article

References (31)

1. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003, 157:1015-1022.
2. Kingsbury A.E., Bandopadhyay R., Silveira-Moriyama L., Ayling H., Kallis C., Sterlacci W., et al. Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov Disord 2010, 25:2508-2515.
3. Santos-García D., de la Fuente-Fernández R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease. JNeurol Sci 2013, 332:136-140.
4. Berg D., Lang A.E., Postuma R.B., Maetzler W., Deuschl G., Gasser T., et al. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol 2013, 12:514-524.
5. Follett K.A., Weaver F.M., Stern M., Hur K., Harris C.L., Luo P., et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. NEngl J Med 2010, 362:2077-2091.
6. Raja M., Bentivoglio A.R. Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson's disease and other disorders. Curr Drug Saf 2012, 7:63-75.
7. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. NEngl J Med 2007, 356:39-46.
8. Tanaka K., Miyake Y., Fukushima W., Sasaki S., Kiyohara C., Tsuboi Y., et al. Intake of Japanese and Chinese teas reduces risk of Parkinson's disease. Parkinsonism Relat Disord 2011, 17:446-450.
9. Hancock D.B., Martin E.R., Stajich J.M., Jewett R., Stacy M.A., Scott B.L., et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007, 64:576-580.
10. Allen M.T., Levy L.S. Parkinson's disease and pesticide exposure - a new assessment. Crit Rev Toxicol 2013, 43:515-534.
11. Sun Y., Chang Y.H., Chen H.F., Su Y.H., Su H.F., Li C.Y. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care 2012, 35:1047-1049.
12. Cereda E., Barichella M., Cassani E., Caccialanza R., Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 2012, 78:1507-1511.
13. Lee Y.C., Lin C.H., Wu R.M., Lin M.S., Lin J.W., Chang C.H., et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 2013, 81:410-416.
14. Undela K., Gudala K., Malla S., Bansal D. Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. JNeurol 2013, 260:158-165.
15. Inzelberg R., Cohen O.S., Aharon-Peretz J., Schlesinger I., Gershoni-Baruch R., Djaldetti R., et al. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 2012, 78:781-786.
16. Kareus S.A., Figueroa K.P., Cannon-Albright L.A., Pulst S.M. Shared predispositions of parkinsonism and cancer: a population-based Pedigree-linked study. Arch Neurol 2012, 69:1572-1577.
17. Xu L., Lin D.C., Yin D., Koeffler H.P. An emerging role of PARK2 in cancer. JMol Med (Berl) 2014, 92:31-42.
18. Chiu C.C., Huang C.C., Chen Y.C., Chen T.J., Liang Y., Lin S.J., et al. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. Intern Med 2013, 52:939-946.
19. Thakkar B., Aronis K.N., Vamvini M.T., Shields K., Mantzoros C.S. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 2013, 62:922-934.
20. Pezzoli G., Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology 2013, 80:2035-2041.
21. Lin H.C., Lin Y.J., Liu T.C., Chen C.S., Chiu W.T. Urbanization and stroke prevalence in Taiwan: analysis of a nationwide survey. JUrban Health 2007, 84:604-614.
22. Health Promotion Administration, Ministry of Health and Welfare. Website: [accessed 30.08.13]. http://www.hpa.gov.tw/BHPNet/Web/Index/Index.aspx.
23. Bo S., Castiglione A., Ghigo E., Gentile L., Durazzo M., Cavallo-Perin P., et al. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. Eur J Endocrinol 2013, 169:117-126.
24. Hsieh M.C., Lee T.C., Cheng S.M., Tu S.T., Yen M.H., Tseng C.H. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012, 2012:413782.
25. Sun L.M., Liang J.A., Chang S.N., Sung F.C., Muo C.H., Kao C.H. Analysis of Parkinson's disease and subsequent cancer risk in Taiwan: a nationwide population-based cohort study. Neuroepidemiology 2011, 37:114-119.
26. Lai S.W., Liao K.F., Lin C.H., Tsai P.Y., Sung F.C. Parkinson's disease and lung cancer: a population-based case-control study in Taiwan. Geriatr Gerontol Int 2013, 13:238-240.
27. Wirdefeldt K., Weibull C.E., Chen H., Kamel F., Lundholm C., Fang F., et al. Parkinson's disease and cancer: a register-based family study. Am J Epidemiol 2014, 179:85-94.
28. Cosyns B., Droogmans S., Rosenhek R., Lancellotti P. Drug-induced valvular heart disease. Heart 2013, 99:7-12.
29. Soskić V., Petrović J., Trajković D., Kidric M. Dopaminergic activity of some ergot alkaloid derivatives: relationship to their chemical structure. Pharmacology 1986, 32:157-166.
30. Liang C., Chen W., Zhi X., Ma T., Xia X., Liu H., et al. Serotonin promotes the proliferation of serum-deprived hepatocellular carcinoma cells via upregulation of FOXO3a. Mol Cancer 2013, 12:14.
31. Horvath J., Burkhard P.R., Bouras C., Kövari E. Etiologies of Parkinsonism in a century-long autopsy-based cohort. Brain Pathol 2013, 23:28-33.